君实生物2025年亏损减少至8.75亿元营收增长28.2%

财中社

Mar 13

　　3月13日，君实生物(688180)公布2025年年报，公司营业收入为25.0亿元，同比上升28.2%；归母净利润自去年同期亏损12.8亿元变为亏损8.75亿元，亏损额有所减少；扣非归母净利润自去年同期亏损12.9亿元变为亏损9.9亿元，亏损额有所减少；经营现金流净额为-5.2亿元，同比增长63.8%；EPS(全面摊薄)为-0.8524元。

　　其中第四季度，公司营业收入为6.93亿元，同比上升2.3%；归母净利润自去年同期亏损3.54亿元变为亏损2.79亿元，亏损额有所减少；扣非归母净利润自去年同期亏损3.5亿元变为亏损3.2亿元，亏损额有所减少；EPS为-0.2722元。

　　截至四季度末，公司总资产123.82亿元，较上年度末增长14.8%；归母净资产为60.3亿元，较上年度末增长2.9%。

　　公司在2025年年度报告中提到，报告期内的经营业务并未发生重大不利变化。公司在创新药物的发现、研发、生产和商业化等方面均取得了源头创新性和突破性进展，现金流情况良好，核心管理层及研发团队保持稳定。

　　在产品管线方面，公司持续推进多款具有国际市场竞争力的创新药物的临床试验，并探索多种联用方案，以最大程度发挥管线协同效应，力推更多优势产品进入注册临床。随着在研产品逐步实现商业化，公司的持续经营能力将不断提升。

（文章来源：财中社）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619196762"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619196762\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619196762?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-13 18:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619196762","market":"sh","top_or_hot":-1,"title":"君实生物2025年亏损减少至8.75亿元 营收增长28.2%","media":"财中社","content":"<html><body><div>\n<p>　　3月13日，<span><a href=\"https://laohu8.com/S/688180\">君实生物</a></span>(688180)公布2025年年报，公司营业收入为25.0亿元，同比上升28.2%；归母净利润自去年同期亏损12.8亿元变为亏损8.75亿元，亏损额有所减少；扣非归母净利润自去年同期亏损12.9亿元变为亏损9.9亿元，亏损额有所减少；经营现金流净额为-5.2亿元，同比增长63.8%；EPS(全面摊薄)为-0.8524元。</p><p>　　其中第四季度，公司营业收入为6.93亿元，同比上升2.3%；归母净利润自去年同期亏损3.54亿元变为亏损2.79亿元，亏损额有所减少；扣非归母净利润自去年同期亏损3.5亿元变为亏损3.2亿元，亏损额有所减少；EPS为-0.2722元。</p><p>　　截至四季度末，公司总资产123.82亿元，较上年度末增长14.8%；归母净资产为60.3亿元，较上年度末增长2.9%。</p><p>　　公司在2025年年度报告中提到，报告期内的经营业务并未发生重大不利变化。公司在<span>创新药</span><span></span>物的发现、研发、生产和商业化等方面均取得了源头创新性和突破性进展，现金流情况良好，核心管理层及研发团队保持稳定。</p><p>　　在产品管线方面，公司持续推进多款具有国际市场竞争力的<span href=\"http://quote.eastmoney.com/unify/r/90.BK1106\" target=\"_blank\" web=\"1\">创新药</span>物的临床试验，并探索多种联用方案，以最大程度发挥管线协同效应，力推更多优势产品进入注册临床。随着在研产品逐步实现商业化，公司的持续经营能力将不断提升。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物2025年亏损减少至8.75亿元 营收增长28.2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物2025年亏损减少至8.75亿元 营收增长28.2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 18:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603133671689256.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月13日，君实生物(688180)公布2025年年报，公司营业收入为25.0亿元，同比上升28.2%；归母净利润自去年同期亏损12.8亿元变为亏损8.75亿元，亏损额有所减少；扣非归母净利润自去年同期亏损12.9亿元变为亏损9.9亿元，亏损额有所减少；经营现金流净额为-5.2亿元，同比增长63.8%；EPS(全面摊薄)为-0.8524元。　　其中第四季度，公司营业收入为6.93亿元，同比上升...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603133671689256.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688180","symbol_name":"君实生物","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603133671689256.html","article_id":"2619196762","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619196762","pubTimestamp":1773399455,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"3月13日，君实生物(688180)公布2025年年报，公司营业收入为25.0亿元，同比上升28.2%；归母净利润自去年同期亏损12.8亿元变为亏损8.75亿元，亏损额有所减少；扣非归母净利润自去年同期亏损12.9亿元变为亏损9.9亿元，亏损额有所减少；经营现金流净额为-5.2亿元，同比增长63.8%；EPS(全面摊薄)为-0.8524元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","01877":"君实生物"},"translate_title":"Junshi Biological's 2025 loss reduces to 875 million yuan, revenue increases by 28.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1.5,"01877":1.5},"content_text":"3月13日，君实生物(688180)公布2025年年报，公司营业收入为25.0亿元，同比上升28.2%；归母净利润自去年同期亏损12.8亿元变为亏损8.75亿元，亏损额有所减少；扣非归母净利润自去年同期亏损12.9亿元变为亏损9.9亿元，亏损额有所减少；经营现金流净额为-5.2亿元，同比增长63.8%；EPS(全面摊薄)为-0.8524元。　　其中第四季度，公司营业收入为6.93亿元，同比上升2.3%；归母净利润自去年同期亏损3.54亿元变为亏损2.79亿元，亏损额有所减少；扣非归母净利润自去年同期亏损3.5亿元变为亏损3.2亿元，亏损额有所减少；EPS为-0.2722元。　　截至四季度末，公司总资产123.82亿元，较上年度末增长14.8%；归母净资产为60.3亿元，较上年度末增长2.9%。　　公司在2025年年度报告中提到，报告期内的经营业务并未发生重大不利变化。公司在创新药物的发现、研发、生产和商业化等方面均取得了源头创新性和突破性进展，现金流情况良好，核心管理层及研发团队保持稳定。　　在产品管线方面，公司持续推进多款具有国际市场竞争力的创新药物的临床试验，并探索多种联用方案，以最大程度发挥管线协同效应，力推更多优势产品进入注册临床。随着在研产品逐步实现商业化，公司的持续经营能力将不断提升。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}